Nynne A.
- Country
- Denmark
- Department
- Section of Gastroenterology, Department of Internal Medicine
Research Overview
- Evaluation of Transmural Healing as a Treatment Target in Moderately to Severely Active Crohn's Disease Using Upadacitinib, Risankizumab, and Ustekinumab
- Efficacy and Safety Evaluation of Oral Zasocitinib in Patients with Moderately to Severely Active Crohn's Disease: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety of Oral Zasocitinib in Moderate to Severe Ulcerative Colitis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 88 of 131 partner sites.
Specializations
Inflammatory Bowel Disease Management
The investigator specializes in treating inflammatory bowel conditions, with particular emphasis on both Crohn's Disease and Ulcerative Colitis in their moderate to severe forms.
- Advanced therapeutic approaches for IBD
- Long-term disease management strategies
- Oral medication effectiveness assessment
Key focus includes evaluating novel therapeutic agents for achieving sustained clinical remission in IBD patients.
Crohn's Disease Expertise
Demonstrates particular interest in transmural healing approaches for Crohn's Disease treatment, exploring innovative therapeutic targets and treatment outcomes.
- Endoscopic response evaluation
- Corticosteroid-free treatment strategies
- Biomarker-based monitoring
Focuses on developing targeted therapeutic approaches for achieving optimal disease control in Crohn's Disease patients.
Treatment Innovation
Actively involved in evaluating novel oral therapeutics and their long-term safety profiles in inflammatory bowel disease treatment.
- Extended treatment protocols
- Safety and tolerability assessments
- Clinical remission evaluation
Specializes in investigating therapeutic approaches for sustained disease management spanning extended treatment periods.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.